Elizabeth Holmes
Biotech

Theranos founder Elizabeth Holmes indicted for alleged fraud, out as CEO

By Rebecca Robbins and Damian Garde

Biotech

China just approved its first cancer immunotherapy drug. Here’s what’s next in the pipeline

By Rebecca Robbins

Sickle cell Bluebird Update
Biotech

New Bluebird data show promising benefits for gene therapy, if they last

By Adam Feuerstein

The Readout LOUD

LISTEN: Problematic parties, NASH nitpicks, and an intimate look at the opioid crisis

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Jennifer Doudna
Business

The University of California will finally be granted a key CRISPR patent

By Sharon Begley

Nasdaq
Biotech

What to watch for in biotech for the rest of 2018

By Damian Garde and Adam Feuerstein

Biotech

Topless women with company logos painted on their bodies danced at unofficial party during BIO convention

By Rebecca Robbins

Sad child
Biotech

Sage Therapeutics gets ‘go faster’ permission from FDA on oral depression drug

By Adam Feuerstein

Crispr DNA
Biotech

CRISPR scientists are in for the long haul. Wall Street is less patient

By Damian Garde

Biotech

For smaller companies, a presence at BIO conference is a big deal

By Jonathan Saltzman — Boston Globe

The Readout LOUD

LISTEN: Twitter vitriol, biotech jargon, and the plight of the CEO

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

The Gates Foundation rolls out details of its new biotech, one without a profit motive

By Helen Branswell

Hong Kong Stocks
Biotech

Can Hong Kong lure biotech without inflating a bubble?

By Rebecca Robbins

Beta-Amyloid Plaques
Biotech

Biogen’s Alzheimer’s drug poses an existential question

By Damian Garde

Vivek Ramaswamy
Biotech

Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy

By Damian Garde

Don't Miss

BIO in 30: Knock on ‘fast followers,’ all about Hong Kong, & Sculley’s next stop

By Casey Ross and Rebecca Robbins

Business

After the ASCO weekend, cancer drug stocks are moving. Here are your winners and losers

By Adam Feuerstein

First Opinion

Biohackers are about open-access to science, not DIY pandemics. Stop misrepresenting us

By Daniel Grushkin

Kendall Square 1987
First Opinion

Boston: the best city in the world to fail in biotech

By Bill Sibold

AP
Biotech

The FDA scuttles Incyte’s billion-dollar hopes in rheumatoid arthritis

By Damian Garde

BIO Manel
Business

BIO conference will feature 25 all-male panels — along with a 30 percent increase in female speakers

By Rebecca Robbins

Biotech

CRISPR advances are coming fast. Here’s your guide

By Sharon Begley

The Readout LOUD

LISTEN: Why fatty livers are a pharma goldmine, a guide to ASCO and BIO, and Trump’s latest drug price promise

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Stem Cell Storage
Health

Stem cell bank opens with backing from leading scientists. Is it worth the money?

By Andrew Joseph

Omeros Bone Marrow
Adam's Take

Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws

By Adam Feuerstein

Biotech

Research in mice may explain CAR-T therapy’s toxic side effects — and how to block them

By Meghana Keshavan

Multiple Myeloma 01
Health

Once quickly lethal and still humbling, multiple myeloma may be in a ‘golden age’ of treatment

By Karen Weintraub

The Readout LOUD

LISTEN: World Cup genetics, the latest Ebola outbreak, and how to fix drug pricing

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Ingestible device
In the Lab

Swallow this: A sensor could monitor gut health via engineered bacteria — and beam results to a smartphone

By Andrew Joseph

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy